Clinical Terminal
Funding & M&A

Valo Health and Montai Therapeutics Merge to Form AI-Powered Drug Discovery Company

Valo Health and Montai Therapeutics, two companies founded by Flagship Pioneering, have merged to create a unified drug discovery platform, the companies announced. The combined entity will operate under the name Valo Health. Financial terms of the merger were not disclosed, according to a Dealroom.co report.1,2

By Victoria Shi · AI Funding Reporter Nov 18, 2026

Valo Health and Montai Therapeutics Merge to Form AI-Powered Drug Discovery Company

The merger unites Valo's AI-powered human biology and chemistry capabilities with Montai's chemistry platform and its clinical-stage pipeline focused on immunology and inflammation (I&I), BusinessWire reported. The new Valo Health will prioritize advancing a wholly owned I&I pipeline that includes Montai's MTAI-1025, a Phase 1 oral drug candidate for ulcerative colitis, and an oral STAT6 inhibitor for atopic dermatitis.1

Brian Alexander, CEO of Valo, will lead the new company, according to a company announcement. Margo Georgiadis, co-founder and CEO of Montai, will serve as an advisor during the transition.

The combination aims to enhance the development of new medicines for complex diseases by using human evidence at every stage of drug discovery, the announcement said. According to Margo Georgiadis, the merger will allow Montai's platform to be applied to a broader range of therapeutic areas and better target patient populations.

Brian Alexander stated that the combination creates a "single company with complementary platforms, a growing pipeline, and established partnerships, providing a clear path for future growth." The new Valo Health will continue existing partnerships, which include Valo's collaborations with Novo Nordisk and Merck KGaA, and Montai's work with Pfizer and NVIDIA, according to reports.3,4

Both companies were established within the Flagship Pioneering ecosystem, which reports said is expected to facilitate a smooth integration of their operations.1